The department has a strong history of extramural funding, especially in the areas of schizophrenia, depression, brain stimulation, and suicide. We have received about $2,000,000 in direct costs support for our extramural research programs since fiscal year 2013, with the strongest support coming from the NIMH.
A phase 3 study to evaluate weight gain of ALKS 3831 compared to Olanzapine in adults
with schizophrenia
Alermes, Inc
PI: Joseph McEvoy, M.D.
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess
the efficacy, safety and tolerability of AVP-786 (deuterated [d6] dextromethorphan
hydrobromide [d6-DM]/duinidine sulfate [Q]) as an adjunctive treatment for patients
with residual schizophrenia.
Avanir Pharmaceuticals, Inc.
PI: Joseph McEvoy, M.D.
A randomized controlled trial of adjunctive tocilizumab in schizophrenia.
NARSAD Independent Investigator Grant
PI: Brian Miller, M.D., Ph.D., MPH
A randomized controlled trial of adjunctive siltuximab in schizophrenia.
Stanley Medical Research Institute
PI: Brian Miller, M.D., Ph.D., MPH
Insomnia, Autonomic Dysfunction, and Suicidal Ideation in Schizophrenia
Augusta University Pilot Study Research Program
PI: Brian Miller, M.D., Ph.D., M.P.H.
A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy,
safety, and tolerability of orally administered BI 409306 during a 52-week treatment
period as an early intervention in patients with attenuated psychosis syndrome.
Boehringer Ingelheim Pharmaceuticals, Inc.
PI: Joseph McEvoy, M.D.
Improving cognition via exercise in schizophrenia
National Institute of Mental Health (NIMH)
PI: Joseph McEvoy, M.D.
Metformin and Lorcaserin for weight loss in people with schizophrenia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
PI: Joseph McEvoy, M.D.
A phase II, 12-week, randomized, double-blind, placebo-controlled, parallel study
to evaluate efficacy, safety, tolerability, and pharmacokinetics of the three dose
levels of TAK-831 in adjunctive treatment of adult patients with negative symptoms
of schizophrenia
Millennium Pharmaceuticals, Inc.
PI: Joseph McEvoy, M.D.
Phase II, A randomized, double-blind, multiple-dose, placebo-controlled study to evaluate
the safety and efficacy of BIIB104 in subjects with cognitive impairment associated
with schizophrenia
Biogen MA, Inc.
PI: Joseph McEvoy, M.D.
Investigation of the Relationship between suicidal ideation and dysfunctional beliefs
about sleep.
PI: W. Vaughn McCall, M.D.
PCORI/TRD-1511-3327
1.2 calendar months
Patient-Centered Outcomes Research Institute (PCORI)
Augumentation versus Switch: Comparative Research Trial for Antidepressant Incomplete
and Non-responders with Treatment Resistant Depression (ASCERTAIN-TRD)
The goal of this randomized clinical trial is to compare the antidepressant effectiveness
of switching treatment resistant depressed patients to either a seratonin-norepinephrine
reuptake inhibitor, versus add-on aripiprazole, versus rTMS
ClinicalTrials.gov Identifier: NCT029772299
PI: W. Vaughn McCall, M.D.
Pilot studies of pupillometry in suicidal and non-suicidal patients
Augusta University
PI: W. Vaughn McCall, M.D.
Co-investigator: Nagy Youssef, M.D.
Reducing suicide ideation through insomnia treatment (REST-IT)
NIH/NIMH
PI: W. Vaughn McCall, M.D.
Co-investigator: Nagy Youssef, M.D.
Reducing suicidal ideation through treatment of nightmares - PTSD (REST-ON)
American Foundation of Suicide Prevention
PI: W. Vaughn McCall, M.D.
Co-investigator: Nagy Youssef, M.D.
A randomized double-blind feasibility study comparing mood and cognitive outcomes
for depressed patients treated with transcranial magnetic stimulation (TMS) combined
with Lumosity cognitive exercises vs. computer game control task.
PI: Peter B. Rosenquist, M.D.
The use of paired pulse TMS measures to assess drug effects on Neuronal Excitability
in Amyotrophic Lateral Sclerosis.
PI: Peter B. Rosenquist, M.D.
Focal Electrically-Administered Seizure Therapy (FEAST): A preliminary study.
MECTA Corporation
PI: Peter B. Rosenquist, M.D. and W. Vaughn McCall, M.D.
Low pulse amplitude focal ECT for treatment-resistant depression
ClinicalTrials.gov Identifier: NCT02583490
PI: Nagy Youssef, M.D.
Focal Electrically-Administered Seizure Therapy (FEAST) (2-site study)
Mecta Corporation (ClinicalTrials.gov Identifier: NCT02535572)
PI: W. Vaughn McCall, M.D.
Co-investigator: Nagy Youssef, M.D.
Magnetic seizure therapy compared to ECT in major depressive disorder: A medication-free
clinical controlled trial
Tanta University, Egypt
Consultant/Co-mentor: Nagy Youssef, M.D.
Augmentation versus Switch: Comparative effectiveness research trial for antidepressant
incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD)
Patient-Centered Outcomes Research Institute (PCOI)
ClinicalTrials.gov (Identifier: NCT02977299)
PI: W. Vaughn McCall, M.D.
Co-investigator: Peter Rosenquist, M.D.
Training Psychiatrists, Nurse Practitioners, and Psychologist to Work Collaboratively
to Address Rural Behavioral Health Disparities
Health Resources and Services Administration
Behavioral Health Workforce Education and Training Program
PI: Jean Pawl
Coinvestigator and Course Director: Peter Rosenquist, M.D.
Novel statistical approaches to analyzing actigraphy data.
PI: W. Vaughn McCall, M.D.
A randomized, double-blind, placebo-controlled, fixed dose study of SD-809 (deutetrabenazine)
for treatment of moderate to severe tardive dyskinesia.
Auspex Pharmaceuticals, Inc.
PI: Joseph McEvoy, M.D.
An open label, long-term safety study of SD-809 (deutetrabenazine) for treatment of
moderate to severe tardive dyskinesia.
Auspex Pharmaceuticals, Inc.
PI: Joseph McEvoy, M.D.
Assessment and outcomes monitoring in psychiatric clinical practice.
PI: Peter B. Rosenquist, M.D.
Screening for clozapine-induced myocarditis-A natrualistic observation study.
PI: Sandarsh Surya, MBBS and Joseph McEvoy, M.D.
A study of inner conflict and psychological well-being in Veterans with PTSD symptoms
ABRC Foundation
PI: Nagy Youssef, M.D.
Assessing medical students knowledge in diagnosis and initial treatment of depression
MCG Academic Affairs
PI: Nagy Youssef, M.D.
Role of skeletal muscle health on poor lifestyle related type 2 diabetes and cardiovascular
disease risk
NIH/NIDDK
Multiple educational grant from Medical Scholar Program for mentorship/education
Consultant: Nagy Youssef, M.D.
Double-blind, Placebo-controlled, Phase 2 trial to test efficacy and safety of AV-1-1
(L-4-chlorokynurenine) as adjunct to current antidepressant therapy in patients with
major depressive disorder (MDD) with an inadequate response to current antidepressants
VistaGen Therapeutics, Inc.
PI: W. Vaughn McCall, M.D.
Co-investigator: Nagy Youssef, M.D.
The effects of a ketogenic diet in veterans with PTSD and TBI
Pilot Study Research Program, Augusta University
Co-Investigator: Nagy Youssef, M.D.
GRISAT Educational Grant (GRU Interprofessional Substance Abuse Training for Health
Professions (GRISAT)
SAMHSA
PI: W. Vaughn McCall, M.D.
Co-investigator: Nagy Youssef, M.D.
A six-week, randomized, double-blind, placebo-controlled, suvorexant augmentation
study of antidepressant treatment of major depressive disorder with residual insomnia
Merck & Co., Inc/Institute for Advanvced Medical Research
PI: W. Vaughn McCall, M.D.
Co-investigator: Nagy Youssef, M.D.
A phase IV, double-blind, placebo-controlled, randomized withdrawal study to evaluate
the persistence of effect and safety of Valbenazine for the treatment of Tardive Dyskinesia
Neurocrine Biosciences, Inc.
PI: Joseph McEvoy, M.D.
